xtensive data exist demonstrating the benefits of lipidlowering medications (LLM), blood pressure lowering medications (BPLM), and aspirin (ASA) for primary prevention of coronary events. [1] [2] [3] However, only 50% to 57% of those at increased cardiovascular risk appear to be on statins and aspirin, indicating that these agents remain underused by high-risk patients and health care providers. 4 -7 Thus, effective interventions that improve their utilization are needed to reduce the burden of cardiovascular diseases (CVD) in high-risk asymptomatic individuals.
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Large prospective studies have consistently demonstrated that assessment of coronary artery calcium scores (CACS) adds incremental cardiovascular risk predictive information. 8, 9 However, to date there are conflicting data whether a higher baseline CACS is associated with increased subsequent utilization of cardiovascular preventive medications. 10 -15 In this study we evaluated the relationship between baseline CACS and rate of initiation and adherence to preventive therapies, specifically, LLM, BPLM, and regular ASA, in men and women ages 45 to 84, from 4 racial/ethnic groups (white, African American, Hispanic, and Chinese) in the prospective Multi-Ethnic Study of Atherosclerosis (MESA). 16 
WHAT IS KNOWN
• To date, there is extensive data that have consistently demonstrated that assessment of coronary artery calcium scores (CACS) adds incremental cardiovascular risk predictive information.
• The relationship of atherosclerosis imaging and subsequent utilization of preventive pharmacotherapy is not clear.
• To date, data from a few small-scale retrospective studies have suggested that presence and high burden of CACS results in increased utilization of preventive medications.
WHAT THE STUDY ADDS
• Our study is the first to demonstrate in a large, prospective, multi-ethnic population based cohort that elevated CACS is associated with nearly one and half fold increased likelihood of initiation of cardiovascular preventive pharmacotherapy as well as a marginal, albeit significant relationship between baseline CACS and continuation rates of these respective medications.
• The additional key methodological strengths of our study overcoming the limitations of prior reports was presence of validated risk factors, taking into account socioeconomic factors which may affect this relationship, as well as verification of medication use at follow-up exams, thus reflecting a more accurate assessment at follow-up.
Methods
The Multi-Ethnic Study of Atherosclerosis (MESA) was initiated in July 2000 to investigate the prevalence, correlates, and progression of subclinical CVD in individuals without known CVD. 16 This prospective cohort study included 6814 women and men ages 45 to 84 years old recruited from 6 US communities (Baltimore, Md; Chicago, Ill; Forsyth County, NC; Los Angeles County, Calif; northern Manhattan, NY; and St Paul, Minn). The cohort includes 38% white (nϭ2624), 28% African American (nϭ1895), 22% Hispanic (nϭ1492), and 12% Chinese (nϭ803) participants. The institutional review boards at participating institutions approved the study, and all participants gave written informed consent at each examination. Baseline medical history, anthropometric measurements, and laboratory data for the present study were taken from the first examination of the MESA cohort (July 2000 to August 2002). These self-administered questionnaires were available in English, Spanish, and Chinese. Information about age, sex, ethnicity, and medical history were obtained by questionnaires. Resting blood pressure was measured 3 times in the seated position, and the average of the second and third readings was recorded. Hypertension was defined as a systolic blood pressure Ն140 mm Hg, diastolic blood pressure Ն90 mm Hg, or use of baseline BPLM. Body mass index was calculated from the equation weight (kg)/height (m 2 ). Total and HDL-C were measured from blood samples obtained after a 12-hour fast. LDL-C was estimated by the Friedewald equation. 17 Current smoking was defined as having smoked a cigarette in the last 30 days. Diabetes mellitus was defined as a fasting glucose Ն126 mg/dL or use of hypoglycemic medications.
Information on socioeconomic factors including highest degree or level of school completed, employment status, total household income, residential status, health insurance coverage, and source of usual medical care was collected from the MESA participants by questionnaires. Education was classified as less than high school, completed high school, bachelor's degree, and graduate or professional school. The total household income was classified as Ͻ$25 000; $25 000 to $49 999; $50 000 to $94 999; and Ն$100 000. Health insurance status was considered as yes (HMO, Medicaid, Medicare, Veteran's health care) or none.
For medication use, the participant was asked to bring to the clinic containers for all medications used during the 2 weeks before the visit. The interviewer then recorded the name of each medication, the prescribed dose, and frequency of administration from the containers. Regular ASA use was defined as self-reported use more than 3 times a week. At baseline (nϭ6814), information of LLM and BPLM was noted in almost all (nϭ6811, 99.9%) individuals, whereas that of regular ASA use was recorded in 6528 (96%) participants.
National Cholesterol Education Program (NCEP) ATP III guidelines were used to assess appropriateness for LLM utilization. 18 The LDL cholesterol cutoffs recommended by the NCEP III guidelines for initiation of LLM are as follows: 0 to 1 risk factors (Ն190 mg/dL), Ն2 risk factors and 10-year coronary heart disease (CHD) risk Յ20% (Ն160 mg/dL), CHD or CHD equivalents with 10-year CHD risk Ն20% (Ն130 mg/dL). 18 JNC VII was used to assess eligibility for BPLM (Ն140/90 mm Hg and Ն130/80 mm Hg for those with diabetes or chronic kidney disease). 19 Individuals with 10-year CHD risk Ն10% were considered eligible for regular ASA use as per American Heart Association guidelines for primary prevention of CVD and stroke. 20 Computed tomography scanning of the chest was performed either with an ECG-triggered (at 80% of the R-R interval) electron-beam computed tomography scanner (Chicago, Los Angeles, and New York field centers; Imatron C-150, Imatron) or with prospectively ECG-triggered scan acquisition at 50% of the R-R interval with a multidetector computed tomography system at acquired 4 simultaneous 2.5-mm slices for each cardiac cycle in a sequential or axial scan mode (Baltimore, Forsyth County, and St Paul field centers; Lightspeed, General Electric or Siemens, Volume Zoom). Each participant was scanned twice. Scans were read centrally at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center to identify and quantify coronary calcification. The CAC measurements among scanning centers and between participants were adjusted with a standard calcium phantom scanned simultaneously with each participant. The mean Agatston score was used in all analyses. Agreement with regard to presence of CAC was high (-statistic, 0.90 to 0.93 between and within readers), and the intraclass correlation coefficient for the Agatston score between readers was 0.99. We standardized results into 4 CAC score categories (0, 1 to 100, 101 to 400, and Ͼ400). These categories have been provided in recent guidelines and represent a simple categorization of the range of CAC scores encountered in clinical practice. 8, 9 Coronary artery calcium scores results were reported back to the participant, and if they consented, to their physician also. In our study, 76% of participants authorized release of the results to their physicians. The letter included a statement that the score was average, below average, or above average for participants of the same age and sex and that the letters did not make specific recommendations regarding medication use or clinical management.
Information on LLM, BPLM, and ASA usage were also assessed at exams 2 and 3 (average of 1.6 and 3.2 years after baseline, respectively). Of the 6814 individuals in the original cohort at baseline, 6233 (91%) and 5,947 (87%) participated in examination 2 and 3. In examination 2 (nϭ6233), information of both LLM and BPLM was present in 5972 (96%) individuals, whereas that of regular ASA use was recorded in 6231 (99.9%) participants. Finally, in examination 3 (nϭ5947), information of both LLM and BPLM was present in 5845 (98%) individuals, whereas that of regular ASA use was recorded in all (100%) participants, respectively.
Overall, 5492 of 6814 (81%) participants had complete information for LLM as well BPLM in all exams (baseline, examination 2, and examination 3). The respective proportion was 82% (nϭ5566/ 6814) for regular ASA use. The proportions of complete medication assessment from examination 1 through examination 3 were similar according to lipid levels, hypertension status and/or CHD risk level.
In this study, we examined initiation of LLM/BPLM/ASA at exam 2 among participants not taking these medications at baseline and continuation of medication use to exam 3 among participants already on medication at baseline.
Statistical Analysis
In our study, meanϮSD and proportions were used to summarize the characteristics of the study sample. Continuous variables were compared by ANOVA, and categorical variables were compared by 2 statistics. The initiation and continuation of medications were fairly common (Ͼ10%) in our cohort; hence, odds ratios would overestimate the relative risk. 21 Relative risk regression was used to model the probability of medication initiation (or continuation) as a function of CACS. The exponentiated parameters ␤ are interpreted as relative risks. Relative risk estimates are presented from the regression model yϭexp(X T ␤). We assumed gaussian error and used robust standard error estimates. Four sets of models were examined in a hierarchical fashion: model 1 (unadjusted); model 2 (adjusted for age, sex, race/ethnicity, and MESA site), and model 3 (adjusted for age, sex, race/ethnicity, MESA site, LDL cholesterol, diabetes mellitus, hypertension, systolic blood pressure, body mass index, and smoking status), and model 4 (adjusted for age, sex, race/ethnicity, MESA site, LDL cholesterol, diabetes mellitus, hypertension, systolic blood pressure, body mass index, smoking status, income, education, and health insurance). All statistical analyses were performed with STATA version 10.0 (Stata Corp, Austin, Tex, http://www.stata.com). The level of significance was set at PϽ0.05 (2-tailed).
The authors had full access to the data and take full responsibility for its integrity. All authors have read and agree to the manuscript as written.
Results
A total of 6814 men and women (47% men; mean age, 62Ϯ10 years) completed the first MESA examination. Half of the study population had no detectable CAC (50%), whereas CACS of 1 to 100, 101 to 400, and Ͼ400 was seen in 26%, 14%, and 10% of individuals, respectively. Table 1 demonstrates the baseline characteristics of study participants according to baseline CACS. Study participants with high CACS were more likely to be men, older, diabetic, and hypertensive. In addition, a high CACS was also associated with low income and high likelihood of presence of health insurance. The prevalence at baseline of reported LLM, BPLM, and ASA increased linearly according to CACS (PϽ0.0001).
Initiation of Cardiovascular Preventive Medications

Lipid-Lowering Medications
There were 5969 participants with information on LLM at both exams 1 and 2. Of these, 4994 (84%) did not report use of LLM at baseline, of whom 15% were appropriate candidates for LLM according NCEP guidelines Overall, 517 (10%) of these individuals reported initiation of LLM between examination 1 and examination 2. Almost all of this new use was due to statin initiation (89%). We observed a significantly higher initiation of LLM among individuals who qualified for treatment according to NCEP guidelines versus those not considered appropriate for LLM treatment by NCEP guidelines (24% versus 8%, PϽ0.0001).
The incidence of new LLM initiation was lowest among those with no CAC (7%), with increasing rates across higher CACS (Table 2) . A higher incidence of LLM initiation across CAC scores was observed whether appropriate (Pϭ0.01) or not (PϽ0.001) according to NCEP ATP III guidelines, respectively. Table 3 demonstrates the unadjusted and adjusted relative risk of LLM initiation according to baseline CACS. In the unadjusted model (model 1), as compared with those with absent CAC, the likelihood of LLM initiation was 2.86-fold higher with CACS Ͼ400. However, the relative risk for LLM initiation was reduced to 1.53 (95% confidence interval [CI], 1.08, 2.15) among those with CACS Ͼ400 compared with those with no detectable CAC in model 4. The interaction between LLM indicated per NCEP and CACS was not statistically significant (Pϭ0. 19 ).
Blood Pressure-Lowering Medications
There were 5969 participants with information on BPLM at both exams 1 and 2. At examination 1, 3766 (63%) individuals were not on any BPLM at examination 1; 87% (nϭ3311) of these were not on any BPLM at examination 2. Overall, 31% of those with no BPLM at examination 1 were considered candidates for drug therapy according to JNC criteria. The use of new BPLM in examination 2 was nearly 3-fold higher among those with CAC Ͼ400 (24%) compared with those without any detectable CAC (9%) ( Table 2 ). The rate of BPLM initiation increased linearly with CAC scores, whether considered hypertensive (Pϭ0.001) or not (Pϭ0.001) according to JNC VII criteria, respectively. The relationship of BPLM initiation based on CAC scores in multivariate analyses is shown in Table 4 . Compared with those with any CAC, the initiation of BPLM was 2.75-fold (95% CI, 2.1 to 3.6) higher among MESA participants with CAC Ͼ400; the relative risk attenuated to 1.55 (95% CI, 1.10 to 2.17) in adjusted model 4. No significant interaction between BPLM indicated per JNC VII and high CACS was observed (Pϭ0.22).
Regular Aspirin Use
There were 5957 participants with information on ASA use at both exams 1 and 2. Of these, 4759 (84%) did not report use of ASA at baseline, with 31% of these meeting eligibility criteria for ASA use. New regular ASA use was reported in 862 of 4759 (18%) of these individuals at the follow-up examination 2. In a fashion similar to LLM and BPLM initiation rates, ASA initiation was lowest among those with no detectable CACS (14%), with increasing rates across higher CACS categories ( Table 2 ). The rate of ASA initiation at MESA examination 2 was higher across with higher CAC scores, whether considered appropriate (PϽ0.001) or not (PϽ0.001) according to AHA recommendations, respectively.
As shown in Table 5 , the relative risks for initiation in unadjusted model with CAC Ͼ400 versus CACϭ0 was 2.24 (95% CI, 1.88 to 2.68); this relationship was attenuated to 1.32 (95% CI, 1.03 to 1.69) after taking into account demographics, MESA site, traditional risk factors, and socioeconomic status (model 4). The interaction term for regular ASA indicated per AHA guidelines and CACS did not achieve statistical significance (Pϭ0.14).Overall, there was no interaction between CACS and sex as well as race/ ethnicity in initiation of LLM, BPLM, and regular ASA use.
Continuation of LLM, BPLM, and Aspirin
In this observational prospective study, 85%, 93%, and 79% of individuals on LLM, BPLM, and ASA at baseline reported that they continued these respective therapies at examination 3. The overall continued used of LLM was observed in 80% with CACSϭ0, compared with 86%, 88%, and 91% with CACS 1 to 100, 101 to 400, and Ͼ400 (Pϭ0.005). In a similar fashion, continued use of BPLM (CACS 0: 91%, CACS 1 to 100: 93%, CACS 101 to 400: 94% and CAC Ͼ400: 96%, Pϭ0.002) and regular ASA (CACS 0: 72%, CACS 1 to 100: 81%, CACS 101 to 400: 80% and CAC Ͼ400: 86%, Pϭ0.001) was statistically significant with higher CAC scores.
The unadjusted and adjusted relative risk ratios of LLM, BPLM, and ASA continuation according to baseline CACS are detailed in Table 6 . Among the MESA participants, the likelihood of continuing these medications with higher CACS was marginally significant in all models. Study participants with CAC Ͼ400 compared with those with no detectable CAC were only 10% (Pϭ0.023), 5% (Pϭ0.002), and 14% (Pϭ0.005) more likely to continue LLM, BPLM, and ASA therapy, respectively, in the adjusted multivariable model 4. No interaction between CACS and sex as well as race/ ethnicity in continuation of LLM, BPLM, and ASA use was observed.
Initiation/Continuation of Cardiovascular Preventive Medications Stratified by Race, Sex, and Education
In a subanalysis, we assessed the effect of high versus low CAC scores (Ͼ100 versus Յ100) on initiation and continuation of LLM, BPLM, and ASA stratified by ethnicity, sex, and educational status (greater than college versus less than college). As shown in Table 7 , in multivariable adjusted analyses, the relative risk ratios for initiation of these medications were similar across all ethnic groups, men and women, and according to educational attainment. No significant interactions with high versus low CAC scores for initiation of these medication was noted across these stratifications (all PϾ0.1). As far as continuation of LLM is concerned (Table 8) , African Americans with high CAC scores (Ͼ100) were more likely to continue LLM as com- pared with Caucasians, and the interaction was statistically significant (PϽ0.0001). No such ethnic differences were noted for continuation of either BPLM or ASA. In addition, the relative risk ratio for continuation of LLM, BPLM, and ASA were similar according to ethnicity, sex, and education status (all PϾ0.1).
Discussion
In this prospective study of multi-ethnic asymptomatic individuals, elevated CACS was associated with nearly 1.5-fold increased likelihood of LLM, BPLM, and regular ASA initiation in a mean follow-up of 1.6 years. In addition, we found a marginal albeit significant relationship between baseline CACS and medication continuation rates. The associations of higher baseline CACS with increased medication initiation and continuation rates remained significant though attenuated when adjusted for traditional risk factors, socioeconomic factors, and health insurance status.
Adequate control of risk factors with behavioral modification as well with appropriate use of LLM, BPLM, and ASA in asymptomatic patients with a wide range of cardiac risk levels has been the cornerstone of preventive efforts to reduce the occurrence of cardiovascular events. The relationship of atherosclerosis imaging and subsequent utilization of preventive pharmacotherapy is not clear. To date, data from a few small-scale studies have suggested that presence and high burden of CACS results in increased utilization of preventive medications. Wong et al 10 in a study of 703 self-referred adults ages 28 to 84 years reported that those with the highest CACS were more likely to begin ASA, LLM, or BPLM. Taylor et al 15 in a recent study compared statin and ASA usage in 1640 men, ages 40 to 50 years, after CAC testing. At 6-year follow-up, statin use was 3-fold more likely among those with any CAC compared with CACϭ0 (48% versus 15%, PϽ0.001) and aspirin use was nearly twice as likely (53% versus 32% PϽ0.01). The incidence of new statin use was Ͼ2 times greater among participants with CAC who were not at NCEP LDL goal at baseline and Ͼ4 times greater among participants with an LDL below the NCEP goal at baseline. 15 Similarly, Orakzai et al 22 have previously shown that those with elevated CACS were almost 3 times more likely to initiate aspirin therapy as compared with subjects with absent CACS. The results of our study are consistent with these observations of increased downstream utilization of preventive medications among those with higher CACS. However, it is important to keep in mind that the initiation of these medications was still relatively low in examination 2 even in those with high CACS within the MESA cohort.
As compared with a consistent relationship of high CACS with initiation of preventive therapies, data on whether atherosclerosis imaging improves medication adherence are conflicting. Kalia et al 13 reported in a study of 505 asymptomatic individuals that LLM continuation was lowest (44%) among those with CAC score in the first quartile (0 to 30), whereas 91% of individuals with baseline CAC score in the fourth quartile (Ն526) adhered to LLM. On the other hand, Taylor et al 15 observed no significant differences according to presence or absence of CAC in either LLM (87% versus 79%, Pϭ0.06) or ASA (79% versus 83%, Pϭ0.36) continuation, respectively.
In our study we found a modest albeit significant relationship between baseline CAC score and medication continuation rates. The high overall medication continuation rate as seen in our study as well as by Taylor et al 15 may have contributed to lack of a stronger association with baseline CACS. Adherence to preventive medication is a vital component for any success in preventing CHD. Although it has been reported that approximately 50% of patients receiving long-term treatment adequately adhere to their prescribed therapies irrespective of underlying disease severity. 23, 24 However, a higher adherence reported by Taylor et al as well seen in our study is encouraging. Whether these improvements are more related to physician input or patient motivation must be evaluated in further studies. In addition, it is important to keep in mind that the adherence reported in MESA may be higher than observed in the general population due to selection of a population that is health-conscious.
This study has a variety of key methodological strengths overcoming the limitations of prior reports. First, most of the studies published to date are of small sample size, retrospective in nature, and include mainly non-Hispanic white individuals who self-referred for CAC testing. 10, 13, 15, 22 The major advantage of our study is that it is a large, prospective, multi-ethnic population based cohort. Second, validated risk factors were measured rather than self-reported, thus reducing the possibility of potential residual confounding. Third, the findings of our study appear to be more robust as we additionally took into account income, education, and health insurance, which may affect the association of higher coronary atherosclerotic burden with medication use. Finally, an important strength is in regard to verification of medication use at follow-up exams. All MESA participants had to bring bottles of the medications in with them and report that they had taken these medications during the previous 2 weeks, which may reflect a more accurate assessment of medications use as compared with self-reported medication in most of the prior reports. 10, 13, 22 Although Taylor et al 15 in a study of nearly 1300 young men (40 to 52 years) confirmed medication use via the military electronic health record, it is important to note that the study population and health care system may not be representative of those observed in the community.
The results of our study should be interpreted in the context of several limitations. First, this study was observational, without a control population that did not receive data on CACS. Second, we relied on self-reported medication use not verified through electronic pharmacy records. This may potentially contribute to the relatively high continuation rates reported in our study. If data on pharmacy refills were available in these participants, this would have provided a more accurate assessment of the continued use of the respective medications. However, assessing the bottles of the medications as well recording if the individuals have taken these medications during the previous 2 weeks is likely to be more accurate that self reported medication use. In our study, 24% of the participants did not authorize release of the results to their physicians; however, further adjustment for this variable did not alter the association of medication adherence and or initiation with increasing CAC burden. In addition, data on all medications in examination 1 to examination 3 were reported in 77% of the participants, with individuals missing having a higher probability of CAC compared with that with complete information (53% versus 49%), which may potentially result in selection bias. However, we believe that this would tend to bias findings toward the null.
In summary, in a large population-based multi-ethnic cohort of men and women, high CACS was independently associated with increased likelihood of LLM, BPLM, and ASA initiation and continuation. However, whether this translates into a reduced rate of cardiovascular events is unknown. Only a randomized clinical trial can clarify whether CAC testing will eventually lead to improved CVD outcomes.
